| PICU PSV Cohort (n=18) |
---|---|
Median age, years (IQR) | 9.5 (5.9-13.7) |
Male/Female, n (%) | 7 (38.9)/11 (61.1) |
Diagnosis, n (%) | Â |
 Refractory Kawasaki disease | 6 (33.3) |
 Takayasu’s arteritis | 5 (27.8) |
 ANCA-associated vasculitis | 4 (22.2) |
 Henoch-Schonlein purpura | 2 (11.1) |
 Primary CNS Vasculitis | 1 (5.6) |
 Others | 0 (0) |
Diagnosis during hospital admission, n (%) | 15 (83.3) |
Treatment during hospitalization | Â |
 Glucocorticoids | 15 (83.3) |
 IVIg | 7 (38.9) |
 Aspirin | 5 (27.8) |
 Cyclophosphamide | 4 (22.2) |
 Disease modifying anti-rheumatic drugs | 2 (11.2) |
 Biologics | 1 (5.6) |
Median hospital length of stay, days (IQR) | 8.5 (4.0-18.8) |